Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

3SBio Files China IND for Anti-Autoimmune mAb from Apexigen

publication date: Aug 17, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
3SBio filed an Investigational New Drug (IND) application with the SFDA to begin clinical trials of a monoclonal antibody drug candidate discovered by Apexigen of San Francisco. SSS07, also known as APX001, will be tested as a treatment for autoimmune and inflammatory diseases. 3SBio completed the development work on the China filing and owns China rights to the molecule. More details....

Stock Symbol: (NSDQ: SSRX)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners